News & Updates

$Continuous smartphone use tied to refractive error in teens$

Continuous smartphone use tied to refractive error in teens

06 Dec 2021 by

A recent study involving Dutch teenagers has found that a higher number of episodes of >20 minutes of continuous smartphone use may lead to more myopic refractive errors. Such association does not exist in those with high outdoor exposure.

Continuous smartphone use tied to refractive error in teens

06 Dec 2021

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

06 Dec 2021

Pre-eclampsia/eclampsia is associated with a higher risk of hospitalization due to heart failure with preserved ejection fraction (HFpEF), reveals a recent study.

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

06 Dec 2021

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021 by

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021

Low appendicular skeletal muscle mass common among older adults in SG

06 Dec 2021 by

Several older adults in Singapore have low appendicular skeletal muscle mass index (ASMI), particularly those who are at high risk for malnutrition, according to a recent study. Smoking, drinking, and low bone mass are other warning signs of low ASMI.

Low appendicular skeletal muscle mass common among older adults in SG

06 Dec 2021

Dry eye disease harms work productivity

06 Dec 2021

Dry eye disease, whether related to Sjögren’s Syndrome or not, disrupts several parameters of work productivity, a recent study has found.

Dry eye disease harms work productivity

06 Dec 2021

PD-1 inhibitors outperform chemo in second-line treatment of advanced oesophageal cancer

06 Dec 2021

In the second-line treatment of patients advanced oesophageal cancer, the use of programmed cell death 1 (PD-1) inhibitors yields more favourable outcomes than chemotherapy across multiple patient subgroups, according to the results of a meta-analysis.

PD-1 inhibitors outperform chemo in second-line treatment of advanced oesophageal cancer

06 Dec 2021

Original New Drug Application Approvals by US FDA (16 - 30 November 2021)

06 Dec 2021

New drug applications approved by US FDA as of 16-30 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.